Nov 14, 2023 4:30pm EST Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Period Activity
Nov 07, 2023 9:28am EST Correcting & Replacing -- Inhibikase Therapeutics to Report Third Quarter Financial Results on November 14, 2023
Nov 07, 2023 8:00am EST Inhibikase Therapeutics to Report Second Quarter Financial Results on November 14, 2023
Oct 16, 2023 7:00am EDT Inhibikase Therapeutics Highlights Unblinded Functional Analysis from the 201 Trial of Risvodetinib in Untreated Parkinson’s Disease and Provides Update on Ongoing Enrollment
Oct 04, 2023 8:30am EDT Inhibikase Therapeutics Receives FDA Orphan Drug Designation for Risvodetinib for the Treatment of Multiple System Atrophy
Sep 20, 2023 8:30am EDT Inhibikase Therapeutics Issues a Letter to Shareholders and Comments on Recent Trading Activity
Aug 24, 2023 8:30am EDT Inhibikase Therapeutics Announces Development of Novel Formulation of risvodetinib
Aug 22, 2023 8:05am EDT Inhibikase Therapeutics to Present at the International Congress of Parkinson's Disease and Movement Disorders
Aug 21, 2023 8:30am EDT Inhibikase Therapeutics Initiates Development of Second Generation c-Abl inhibitors and names IkT-148009 as risvodetinib
Aug 17, 2023 8:30am EDT Inhibikase Therapeutics Announces Completion of the 501 Bioequivalence Study of IkT-001Pro